Evidence map›Paper›PMID 41191051›Full record

Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026

Evaluation of serum tumor markers in assessing the efficacy of TP (Paclitaxel plus Carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual target therapy in HER2-positive breast cancer.

Lei Wang, Yuqing Yang, Jiang Wu, Fengqiang Cui, Jing Yu, Jixin Yang, Nanlin Li

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lei Wang *Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Yuqing Yang *Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Jiang WuDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Fengqiang CuiDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Jing YuDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Jixin YangDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China.
Nanlin LiDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xi'an, 710032, Shanxi, China. nanlin-74@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to evaluate the efficacy of TP (paclitaxel plus carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual-target therapy for HER2-positive breast cancer using serum tumor markers. A total of 96 patients with HER2-positive breast cancer treated at our hospital from January 2021 to January 2023 were selected and randomly divided into a control group and a study group, with 48 cases in each group. The efficacy and safety of the treatments were compared between the two groups. Serum levels of CEA, CA125, and CA153 were measured before and after treatment. After treatment, the overall response rate and disease control rate in the study group were significantly higher than those in the control group (P < 0.05). There were no significant differences in serum levels of CEA, CA125, and CA153 between the two groups before treatment (P > 0.05). However, after treatment, the serum levels of CEA, CA125, and CA153 in the study group were significantly lower than those in the control group (P < 0.05). ROC curve analysis showed that the combined prediction of CEA, CA125, and CA153 had higher AUC, sensitivity, and specificity compared to individual markers. There were no significant differences between the two groups in terms of liver function abnormalities, hemoglobin reduction, platelet reduction, cardiotoxicity, gastrointestinal symptoms, and joint muscle pain (P > 0.05). Evaluating the efficacy of TP (paclitaxel plus carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual-target therapy for HER2-positive breast cancer using serum tumor markers has significant clinical value.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsTrastuzumabAdultAgedAntibodies, Monoclonal, HumanizedCarboplatinErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPaclitaxelTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkers, TumorCarboplatinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelpertuzumabTrastuzumabDual-targetEfficacyHER2-positive breast cancerPertuzumabSerum tumor markersTP (Paclitaxel plus Carboplatin) chemotherapyTrastuzumab

Identifiers

PMID41191051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.